KEAP1-NRF2 Pathway as a Novel Therapeutic Target for EGFR-Mutant Non-small Cell Lung Cancer
We identified that NRF2 inhibition enhanced cell death and inhibited tumor growth in tyrosine kinase inhibitor (TKI)-resistant lung cancer with EGFR-mutation. Thus, NRF2 modulation may be a novel therapeutic strategy to overcome the resistance to EGFR-TKIs.
Authors
- Hyewon Seo (ORCID: https://orcid.org/0000-0003-0533-8863)
- Junyang Jung (ORCID: https://orcid.org/0000-0003-3946-5406)
- Heejin Lim
- Seung Hyeun Lee (ORCID: https://orcid.org/0000-0002-7666-313X)
- Kiyong Na (ORCID: https://orcid.org/0000-0003-4220-6755)
- Taewoo Kim (ORCID: https://orcid.org/0000-0003-1115-2707)
- Jae‐Sun Choi (ORCID: https://orcid.org/0000-0003-2069-3361)
- Jiwon Kim (ORCID: https://orcid.org/0000-0001-6748-7624)
- Hye-Min Kang
Institutions
- Kyung Hee University (KR)
- Kyung Hee University Medical Center (KR)
- Korea Basic Science Institute (KR)
- Daegu-Gyeongbuk Medical Innovation Foundation (KR)
Publication Details
- Journal
- Tuberculosis & respiratory diseases
- Published
- 2024-09-23
- DOI
- https://doi.org/10.4046/trd.2024.0087
- Citations
- 4
- Primary Topic
- Genomics, phytochemicals, and oxidative stress
- Type
- article
- Field-Weighted Citation Impact
- 0.94